# Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma

> **NCT00594126** · PHASE1 · COMPLETED · sponsor: **Geron Corporation** · enrollment: 20 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Imetelstat Sodium (GRN163L)

## Key facts

- **NCT ID:** NCT00594126
- **Lead sponsor:** Geron Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2011-07
- **Final completion:** 2011-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00594126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00594126, "Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00594126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*